Display options
Cite
Ekpanyapong S, Bunchorntavakul C, Reddy KR. COVID-19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later. J Viral Hepat. 2021;29(1):4-20doi: 10.1111/jvh.13590.
Ekpanyapong, S., Bunchorntavakul, C., & Reddy, K. R. (2022). COVID-19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later. Journal of viral hepatitis, 29(1), 4-20. https://doi.org/10.1111/jvh.13590
Ekpanyapong, Sirina, et al. "COVID-19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later." Journal of viral hepatitis vol. 29,1 (2022): 4-20. doi: https://doi.org/10.1111/jvh.13590
Ekpanyapong S, Bunchorntavakul C, Reddy KR. COVID-19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later. J Viral Hepat. 2022 Jan;29(1):4-20. doi: 10.1111/jvh.13590. Epub 2021 Aug 12. PMID: 34352133; PMCID: PMC8446947.
Copy Download .nbib Format: NLM
Share it on

J Viral Hepat. 2022 Jan;29(1):4-20. doi: 10.1111/jvh.13590. Epub 2021 Aug 12.

COVID-19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later.

Journal of viral hepatitis

Sirina Ekpanyapong, Chalermrat Bunchorntavakul, K Rajender Reddy

Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Medicine, Rajavithi Hospital, Bangkok, Thailand.
  2. Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

PMID: 34352133 PMCID: PMC8446947 DOI: 10.1111/jvh.13590

Abstract

Globally, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) has been a major cause for significant morbidity and mortality. Since the start of the pandemic, several hepato-biliary manifestations in coronavirus disease 2019 (COVID-19) have been described and unique considerations raised. The review aims to summarize the pathogenesis and hepato-biliary manifestations in COVID-19 and discuss the similarities, contrasting features and disease-specific management across a range of hepato-biliary diseases from the EAST and the WEST. Published studies and regional society guidelines from the EAST and the WEST were comprehensively reviewed and summarized. A wide range of hepato-biliary manifestations, including the infrequent and chronic manifestation of cholangiopathy, has been observed in COVID-19. The pathogenesis of liver injury is multifactorial and with scant evidence for a direct SARS-CoV-2 infection of the liver. Patients with non-alcoholic fatty liver disease, cirrhosis, and liver cancer are potentially at increased risk for severe COVID-19, and there are unique considerations in chronic hepatitis B or C, hepatocellular carcinoma, and in those immunosuppressed such as autoimmune hepatitis or liver transplant recipients. With the surges in SARS-CoV-2 infection, liver transplant activity has variably been impacted. Preliminarily, SARS-CoV-2 vaccines appear to be safe in those with chronic liver disease and in transplant recipients, while emerging data suggest the need for a third dose in immunosuppressed patients. In conclusion, patients with chronic liver disease, particularly cirrhosis, and liver transplant recipients, are vulnerable to severe COVID-19. Over the past year, several unique considerations have been highlighted across a spectrum of hepato-biliary diseases. Vaccination is strongly recommended for those with chronic liver disease and liver transplant recipients.

© 2021 John Wiley & Sons Ltd.

Keywords: COVID-19; cirrhosis; hepatitis; liver transplant; vaccination

References

  1. Fix OK, Hameed B, Fontana RJ, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology. 2020;72(1):287-304. - PubMed
  2. Zhang C, Shi L, Wang F-S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428-430. - PubMed
  3. Ji D, Zhang D, Yang T, et al. Effect of COVID-19 on patients with compensated chronic liver diseases. Hepatol Int. 2020;14(5):701-710. - PubMed
  4. Qiu H, Wander P, Bernstein D, Satapathy SK. Acute on chronic liver failure from novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Liver Int. 2020;40(7):1590-1593. - PubMed
  5. Iavarone M, D'Ambrosio R, Soria A, et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020;73(5):1063-1071. - PubMed
  6. Jothimani D, Venugopal R, Abedin MF, Kaliamoorthy I, Rela M. COVID-19 and the liver. J Hepatol. 2020;73(5):1231-1240. - PubMed
  7. Li Y, Xiao S-Y. Hepatic involvement in COVID-19 patients: Pathology, pathogenesis, and clinical implications. J Med Virol. 2020;92(9):1491-1494. - PubMed
  8. Case fatality rate of the ongoing COVID-19 pandemic. Accessed November 14, 2020. https://ourworldindata.org/mortality-risk-covid - PubMed
  9. WHO Coronavirus Disease (COVID-19) Dashboard Accessed June 12, 2021. https://covid19.who.int/?gclid=EAIaIQobChMIqqrtlK2C7QIVGxwrCh3LcQm2EAAYASAAEgKaefD_BwE - PubMed
  10. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-513. - PubMed
  11. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. - PubMed
  12. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. - PubMed
  13. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020;20(4):425-434. - PubMed
  14. Xu X-W, Wu X-X, Jiang X-G, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ (Clin Res). 2020;368:m606. - PubMed
  15. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Resp Med. 2020;8(5):475-481. - PubMed
  16. Cai Q, Huang D, Ou P, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy. 2020;75(7):1742-1752. - PubMed
  17. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787-1799. - PubMed
  18. Fan Z, Chen L, Li J, et al. Clinical features of covid-19-related liver functional abnormality. Clin Gastroenterol Hepatol. 2020;18(7):1561-1566. - PubMed
  19. Fan Z, Chen L, Li J, et al. Clinical features of COVID-19 related liver damage. medRxiv. https://doi.org/10.1101/2020.02.26.20026971 - PubMed
  20. Huang Y, Yang R, Xu Y, Gong P. Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China. medRxiv. https://doi.org/10.1101/2020.02.27.20029009 - PubMed
  21. Cao M, Zhang D, Wang Y, et al. Clinical features of patients infected with the 2019 novel coronavirus (COVID-19) in Shanghai, China. medRxiv. https://doi.org/10.1101/2020.03.04.20030395 - PubMed
  22. Cai Q, Huang D, Yu H, et al. COVID-19: Abnormal liver function tests. J Hepatol. 2020;73(3):566-574. - PubMed
  23. Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China. Liver Int. 2020;40(9):2095-2103. - PubMed
  24. Vespa E, Pugliese N, Piovani D, et al. Liver tests abnormalities in COVID-19: trick or treat? J Hepatol. 2020;73(5):1275-1276. - PubMed
  25. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected With SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574-1581. - PubMed
  26. Cholankeril G, Podboy A, Aivaliotis VI, et al. High prevalence of concurrent gastrointestinal manifestations in patients with severe acute respiratory syndrome coronavirus 2: Early experience From California. Gastroenterology. 2020;159(2):775-777. - PubMed
  27. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically Ill patients With COVID-19 in Washington State. JAMA. 2020;323(16):1612-1614. - PubMed
  28. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-2059. - PubMed
  29. Tang C, Zhang K, Wang W, et al. Clinical characteristics of 20,662 patients with COVID-19 in mainland China: A systemic review and meta-analysis. medRxiv. https://doi.org/10.1101/2020.04.18.20070565 - PubMed
  30. Ji D, Qin E, Xu J, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol. 2020;73(2):451-453. - PubMed
  31. Chai X, Hu L, Zhang Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. https://doi.org/10.1101/2020.02.03.931766 - PubMed
  32. Clinical best practice advice for hepatology and liver transplant providers during the covid-19 pandemic: AASLD expert panel consensus statement (Released: June 25, 2020). https://www.aasld.org/sites/default/files/2020-06/AASLD-COVID19-ExpertPanelConsensusStatement-June252020-v2-FINAL.pdf - PubMed
  33. Lei F, Liu YM, Zhou F, et al. Longitudinal association between markers of liver injury and mortality in COVID-19 in China. Hepatology. 2020;72(2):389-398. - PubMed
  34. Liu W, Tao ZW, Wang L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J. 2020;133(9):1032-1038. - PubMed
  35. Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Am J Transplant. 2020;20(7):1800-1808. - PubMed
  36. Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020;40(5):998-1004. - PubMed
  37. Qi X, Liu C, Jiang Z, et al. Multicenter analysis of clinical characteristics and outcomes in patients with COVID-19 who develop liver injury. J Hepatol. 2020;73(2):455-458. - PubMed
  38. Lu X, Zhang L, Du H, et al. SARS-CoV-2 Infection in Children. N Engl J Med. 2020;382(17):1663-1665. - PubMed
  39. Clinical insights for hepatology and liver transplant providers during the COVID-19 pandemic (Released: April 7, 2020). https://www.aasld.org/sites/default/files/2020-04/AASLD-COVID19-ClinicalInsights-4.07.2020-Final.pdf - PubMed
  40. Major Updates to COVID-19 Clinical Insights Document (Released April 16, 2020). https://www.aasld.org/sites/default/files/2020-04/COVID19-ClinicalInsightsUpdates-4162020.pdf - PubMed
  41. Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61(6):1385-1396. - PubMed
  42. Boettler T, Marjot T, Newsome PN, et al. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. JHEP Reports. 2020;2(5):100169. - PubMed
  43. Banales JM, Huebert RC, Karlsen T, Strazzabosco M, LaRusso NF, Gores GJ. Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol. 2019;16(5):269-281. - PubMed
  44. Tian S, Xiong Y, Liu H, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol. 2020;33(6):1007-1014. https://doi.org/10.1038/s41379-020-0536-x - PubMed
  45. Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459-468. - PubMed
  46. Schaefer EAK, Arvind A, Bloom PP, Chung RT. Interrelationship between coronavirus infection and liver disease. Clin Liv Dis. 2020;15(5):175-180. - PubMed
  47. Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382(24):2327-2336. - PubMed
  48. Li J, Fan J-G. Characteristics and mechanism of liver injury in 2019 coronavirus disease. J Clin Transl Hepatol. 2020;8(1):13-17. - PubMed
  49. Surveillance Epidemiology of Coronavirus (COVID-19) Under Research Exclusion (SECURE)-CIRRHOSIS Registry, Updates and Data. Accessed May 7, 2021. https://covidcirrhosis.web.unc.edu/updates-and-data/ - PubMed
  50. COVID-19 in Patients with Liver Disease or Transplantation (COVID-Hep) Registry. Accessed May 7, 2021. https://www.covid-hep.net/img/update_20200825.pdf - PubMed
  51. Weisberg IS, Jacobson IM. Cardiovascular diseases and the liver. Clin Liver Dis. 2011;15(1):1-20. - PubMed
  52. Faruqui S, Okoli FC, Olsen SK, et al. Cholangiopathy after severe COVID-19: clinical features and prognostic implications. Am J Gastroenterol. 2021;116(7):1414-1425. - PubMed
  53. Roth NC, Kim A, Vitkovski T, et al. Post-COVID-19 cholangiopathy: a novel entity. Am J Gastroenterol. 2021;116(5):1077-1082. - PubMed
  54. Lippi G, de Oliveira MHS, Henry BM. Chronic liver disease is not associated with severity or mortality in Coronavirus disease 2019 (COVID-19): a pooled analysis. Eur J Gastro Hepatol. 2021;33(1):114-115. - PubMed
  55. Williamson E, Walker AJ, Bhaskaran KJ, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv. https://doi.org/10.1101/2020.05.06.20092999 - PubMed
  56. Singh S, Khan A. Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: A Multicenter Research Network Study. Gastroenterology. 2020;159(2):768-771.e763. - PubMed
  57. Marjot T, Moon AM, Cook JA, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. J Hepatol. 2021;74(3):567-577. - PubMed
  58. Zhang B, Huang W, Zhang S. Clinical features and outcomes of Coronavirus Disease 2019 (COVID-19) patients with chronic hepatitis B virus infection. Clin Gastroenterol Hepatol. 2020;18(11):2633-2637. - PubMed
  59. Blach S, Kondili LA, Aghemo A, et al. Impact of COVID-19 on global HCV elimination efforts. J Hepatol. 2021;74(1):31-36. - PubMed
  60. Lau G, Sharma M. Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations. Hep Intl. 2020;1-14. - PubMed
  61. Di Giorgio A, Nicastro E, Speziani C, et al. Health status of patients with autoimmune liver disease during SARS-CoV-2 outbreak in northern Italy. J Hepatol. 2020;73(3):702-705. - PubMed
  62. Gerussi A, Rigamonti C, Elia C, et al. Coronavirus Disease 2019 in autoimmune hepatitis: a lesson from immunosuppressed patients. Hepatol Commun. 2020;4(9):1257-1262. - PubMed
  63. Boettler T, Newsome PN, Mondelli MU, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2(3):100113. - PubMed
  64. Targher G, Mantovani A, Byrne CD, et al. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020;69(8):1545-1547. - PubMed
  65. Hashemi N, Viveiros K, Redd WD, et al. Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: A multicentre United States experience. Liver Int. 2020;40(10):2515-2521. - PubMed
  66. Shalimar EA, Vaishnav M, et al. Poor outcomes in patients with cirrhosis and Corona Virus Disease-19. Indian J Gastroenterol. 2020;39(3):285-291. - PubMed
  67. Bajaj JS, Garcia-Tsao G, Biggins SW, et al. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut. 2021;70(3):531-536. https://doi.org/10.1136/gutjnl-2020-322118 - PubMed
  68. Liu H, He X, Wang Y, et al. Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation. Hep Intl. 2020;14(4):432-436. - PubMed
  69. Qin J, Wang H, Qin X, et al. Perioperative presentation of COVID-19 disease in a liver transplant recipient. Hepatology. 2020;72(4):1491-1493. - PubMed
  70. D’Antiga L. Coronaviruses and immunosuppressed patients: The facts during the third epidemic. Liver Transpl. 2020;26(6):832-834. - PubMed
  71. Rodriguez-Peralvarez M, Salcedo M, Colmenero J, Pons JA. Modulating immunosuppression in liver transplant patients with COVID-19. Gut. 2021;70(7):1412-1414. - PubMed
  72. Becchetti C, Zambelli MF, Pasulo L, et al. COVID-19 in an international European liver transplant recipient cohort. Gut. 2020;69(10):1832-1840. - PubMed
  73. Colmenero J, Rodriguez-Peralvarez M, Salcedo M, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol. 2021;74(1):148-155. - PubMed
  74. Webb GJ, Marjot T, Cook JA, et al. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. The Lancet Gastroenterology & Hepatology. 2020;5(11):1008-1016. - PubMed
  75. Ravanan R, Callaghan CJ, Mumford L, et al. SARS-CoV-2 infection and early mortality of waitlisted and solid organ transplant recipients in England: A national cohort study. Am J Transplant. 2020;20(11):3008-3018. - PubMed
  76. Lee BT, Perumalswami PV, Im GY, et al. COVID-19 in liver transplant recipients: an initial experience From the US epicenter. Gastroenterology. 2020;159(3):1176-1178 e1172. - PubMed
  77. Belli LS, Duvoux C, Karam V, et al. COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry. Lancet Gastroenterol Hepatol. 2020;5(8):724-725. - PubMed
  78. Polak WG, Fondevila C, Karam V, et al. Impact of COVID-19 on liver transplantation in Europe: alert from an early survey of European Liver and Intestine Transplantation Association and European Liver Transplant Registry. Transpl Int. 2020;33(10):1244-1252. - PubMed
  79. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335-337. - PubMed
  80. Lee LYW, Cazier J-B, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. The Lancet. 2020;395(10241):1919-1926. - PubMed
  81. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol. 2020;6(7):1108-1110. - PubMed
  82. Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894-901. - PubMed
  83. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. - PubMed
  84. Mehta V, Goel S, Kabarriti R, et al. Case fatality rate of cancer patients with COVID-19 in a New York Hospital System. Cancer Discov. 2020;10(7):935-941. - PubMed
  85. Kudo M, Kurosaki M, Ikeda M, et al. Treatment of hepatocellular carcinoma during the COVID-19 outbreak: The Working Group report of JAMTT-HCC. Hepatol Res. 2020;50(9):1004-1014. - PubMed
  86. Chan SL, Kudo M. Impacts of COVID-19 on liver cancers: during and after the pandemic. Liver Cancer. 2020;9(5):491-502. - PubMed
  87. Amaddeo G, Brustia R, Allaire M, et al. Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area. JHEP Rep. 2021;3(1):100199. - PubMed
  88. Iavarone M, Sangiovanni A, Carrafiello G, Rossi G, Lampertico P. Management of hepatocellular carcinoma in the time of COVID-19. Ann Oncol. 2020;31(8):1084-1085. - PubMed
  89. Loupy A, Aubert O, Reese PP, Bastien O, Bayer F, Jacquelinet C. Organ procurement and transplantation during the COVID-19 pandemic. The Lancet. 2020;395(10237):e95-e96. - PubMed
  90. de Vries APJ, Alwayn IPJ, Hoek RAS, et al. Immediate impact of COVID-19 on transplant activity in the Netherlands. Transpl Immunol. 2020;61:101304. - PubMed
  91. Gruttadauria S. Preliminary analysis of the impact of the coronavirus disease 2019 outbreak on Italian liver transplant programs. Liver Transpl. 2020;26(7):941-944. - PubMed
  92. Maggi U, De Carlis L, Yiu D, et al. The impact of the COVID-19 outbreak on liver transplantation programs in Northern Italy. Am J Transplant. 2020;20(7):1840-1848. - PubMed
  93. Thorburn D, Taylor R, Whitney J, et al. Resuming liver transplantation amid the COVID-19 pandemic. Lancet Gastroenterol Hepatol. 2021;6(1):12-13. - PubMed
  94. Pathanki AM, Mirza DF. Liver transplantation during the times of COVID-19 - viruses, vaccines and beyond. J Clin Exp Hepatol. 2021;11(4):411-413. https://doi.org/10.1016/j.jceh.2021.1004.1014 - PubMed
  95. Pahari H, Shellagi N, Nath B. Deceased donor liver transplantation in India in the COVID-19 Era: current scenario and future perspectives. Transpl Proc. 2020;52(9):2684-2687. - PubMed
  96. De Carlis R, Vella I, Incarbone N, et al. Impact of the COVID-19 pandemic on liver donation and transplantation: A review of the literature. World J Gastroenterol. 2021;27(10):928-938. - PubMed
  97. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615. - PubMed
  98. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416. - PubMed
  99. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181-192. - PubMed
  100. Aggeletopoulou I, Davoulou P, Konstantakis C, Thomopoulos K, Triantos C. Response to hepatitis B vaccination in patients with liver cirrhosis. Rev Med Virol. 2017;27(6):e1942. - PubMed
  101. Duchini A, Hendry RM, Nyberg LM, Viernes ME, Pockros PJ. Immune response to influenza vaccine in adult liver transplant recipients. Liver Transpl. 2001;7(4):311-313. - PubMed
  102. McCashland TM, Preheim LC, Gentry MJ. Pneumococcal vaccine response in cirrhosis and liver transplantation. J Infect Dis. 2000;181(2):757-760. - PubMed
  103. Ou MT, Boyarsky BJ, Motter JD, et al. Safety and reactogenicity of 2 doses of SARS-CoV-2 vaccination in solid organ transplant recipients. Transplantation. 2021. Ahead of Print. - PubMed
  104. Boyarsky BJ, Werbel WA, Avery RK, et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA. 2021;325(17):1784-1786. - PubMed
  105. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-Dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325(21):2204-2206. - PubMed
  106. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021. - PubMed
  107. Fu Y, Zhu R, Bai T, et al. Clinical features of patients infected with coronavirus disease 2019 with elevated liver biochemistries: A multicenter, retrospective study. Hepatology. 2021;73(4):1509-1520. - PubMed
  108. Wang Y, Liu S, Liu H, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020;73(4):807-816. - PubMed
  109. Huang R, Zhu L, Wang J, et al. Clinical features of patients with COVID-19 patients with nonalcoholic fatty liver disease. Hepatol Commun. 2020;4(12):1758-1768. https://doi.org/10.1002/hep4.1592. - PubMed
  110. Zhou YJ, Zheng KI, Wang XB, et al. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis. J Hepatol. 2020;73(3):719-721. - PubMed
  111. Yadav DK, Singh A, Zhang Q, et al. Involvement of liver in COVID-19: systematic review and meta-analysis. Gut. 2021;70(4):807-809. - PubMed
  112. Dhampalwar S, Saigal S, Choudhary N, et al. Outcomes of coronavirus disease 2019 in living donor liver transplant recipients. Liver Transpl. 2020;26(12):1665-1666. - PubMed
  113. Sarin SK, Choudhury A, Lau GK, et al. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hep Intl. 2020;14(5):690-700. - PubMed
  114. Phipps MM, Barraza LH, LaSota ED, et al. Acute Liver Injury in COVID-19: prevalence and association with clinical outcomes in a large U.S. Cohort. Hepatology. 2020;72(3):807-817. - PubMed
  115. Hundt MA, Deng Y, Ciarleglio MM, Nathanson MH, Lim JK. Abnormal liver tests in COVID-19: A retrospective observational cohort study of 1,827 Patients in a major U.S. Hospital Network. Hepatology. 2020;72(4):1169-1176. - PubMed
  116. Bloom PP, Meyerowitz EA, Reinus Z, et al. Liver biochemistries in hospitalized patients With COVID-19. Hepatology. 2021;73(3):890-900. - PubMed
  117. Clift AK, Coupland CAC, Keogh RH, et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ (Clin Res ed). 2020;371:m3731. - PubMed
  118. Rabiee A, Sadowski B, Adeniji N, et al. Liver Injury in Liver transplant recipients with coronavirus disease 2019 (COVID-19): U.S. multicenter experience. Hepatology. 2020;72(6):1900-1911. - PubMed
  119. Kates OS, Haydel BM, Florman SS, et al. COVID-19 in solid organ transplant: a multi-center cohort study. Clin Infect Dis. 2020;ciaa1097. https://doi.org/10.1093/cid/ciaa1097 - PubMed
  120. Belli LS, Fondevila C, Cortesi PA, et al. Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA/ELTR Multi-center European Study. Gastroenterology. 2021;160(4):1151-1163 e1153. - PubMed
  121. Verhelst X, Somers N, Geerts A, Degroote H, Van Vlierberghe H. Health status of patients with autoimmune hepatitis is not affected by the SARS-CoV-2 outbreak in Flanders, Belgium. J Hepatol. 2021;74(1):240-241. - PubMed
  122. Butt AA, Yan P, Chotani RA, Shaikh OS. Mortality is not increased in SARS-CoV-2 infected persons with hepatitis C virus infection. Liver Int. 2021;41(8):1824-1831. - PubMed
  123. Kim D, Adeniji N, Latt N, et al. Predictors of outcomes of COVID-19 in patients with chronic liver disease: US Multi-center Study. Clin Gastroenterol Hepatol. 2021;19(7):1469-1479. - PubMed
  124. Chen X, Jiang Q, Ma Z, et al. Clinical characteristics of hospitalized patients with SARS-CoV-2 and hepatitis B virus Co-infection. medRxiv. 2020;35(6):842-845. - PubMed
  125. Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020;212(9):416-420. - PubMed
  126. Sachdeva S, Khandait H, Kopel J, Aloysius MM, Desai R, Goyal H. NAFLD and COVID-19: a pooled analysis. SN Compr Clin Med. 2020;1-4. - PubMed
  127. Forlano R, Mullish BH, Mukherjee SK, et al. In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. PLoS One. 2020;15(10):e0240400. - PubMed
  128. Mahamid M, Nseir W, Khoury T, et al. Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study. Eur J Gastro Hepatol. 2020. https://doi.org/10.1097/MEG.0000000000001902 - PubMed
  129. Bramante C, Tignanelli CJ, Dutta N, et al. Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19. medRxiv. https://doi.org/10.1101/2020.09.01.20185850 - PubMed
  130. Gao Y, Chen Y, Liu M, Shi S, Tian J. Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis. The Journal of Infection. 2020;81(2):e93-e95. - PubMed
  131. Gao F, Zheng KI, Gu JY, George J, Zheng MH. COVID-19 and liver transplantation: Lessons learned from three reported cases. Transpl Infect Dis. 2020;22(4):e13335. - PubMed
  132. Varghese J, Malleeswaran S, Patcha RV, et al. A multicentric experience on living donor liver transplantation in COVID-19 hotspots in India. Liver Transpl n/a(n/a). - PubMed
  133. Fernández-Ruiz M, Andrés A, Loinaz C, et al. COVID-19 in solid organ transplant recipients: A single-center case series from Spain. Am J Transplant. 2020;20(7):1849-1858. - PubMed
  134. Webb GJ, Moon AM, Barnes E, Barritt AS, Marjot T. Determining risk factors for mortality in liver transplant patients with COVID-19. Lancet Gastroenterol Hepatol. 2020;5(7):643-644. - PubMed
  135. Heimbach JK, Taner T. SARS-CoV-2 infection in liver transplant recipients: collaboration in the time of COVID-19. Lancet Gastroenterol Hepatol. 2020;5(11):958-960. - PubMed
  136. Bhoori S, Rossi RE, Citterio D, Mazzaferro V. COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. Lancet Gastroenterol Hepatol. 2020;5(6):532-533. - PubMed
  137. Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Crit Care. 2020;24(1):179. - PubMed
  138. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907-1918. - PubMed

Substances

MeSH terms

Publication Types